drugset / Trial / NCT02015533

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants

NCT02015533 ↗

Phase 1 Withdrawn Janssen Pharmaceutical K.K.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to assess the safety, pharmacokinetics (what the body does to the drug) and immunogenicity (ability of a particular substance to provoke an immune response in the human body) of CR8020 in japanese healthy participants

Timeline

Start
2013-12
Primary completion
2014-01
Completion
2014-04

Outcome

Outcome not reported

Stopped: “The study was terminated due to an unexpected preliminary result obtained from the study with CR8020.”

Drugs

EvaluationDrugModalityDoseRoute
Subject CR8020 Monoclonal antibody 50 mg/kg Intravenous

Indications

No indication recorded.